319PA randomized, open label, phase II study of prophylactic octreotide (OCT) to prevent/reduce the frequency and severity of diarrhea in patients (pts) receiving lapatinib (LAP) with capecitabine (CAP) for the treatment of metastatic breast cancer (mBC). (23rd October 2018) - Krivorotko, P; Karaszewska, B; Chan, S; Wieczorek-Rutkowska, M; Sarosiek, T; Shomova, M V; Ovchinnikova, E; Zarate, J P; Babanrao Pisal, C; Smith, L; Manikhas, A